Prodia Broke the MURI Record for Indonesia’s Most Free Genetic Tests Provided for People With Rare Diseases

JAKARTA, 9 May 2023 – PT Prodia Widyahusada Tbk (ticker symbol: PRDA) was presented with an award from the Indonesian World Records Museum (MURI) on its 50th anniversary. The award recognized the most genetic tests ever provided for people with rare diseases in Indonesia as part of the company’s corporate social responsibility (CSR) efforts. The program has seen Prodia successfully provide free-of-charge genetic tests for people with rare diseases, commonly referred to by Indonesians as orang dengan penyakit langka or odalangka. The award was bestowed on behalf of the company on Andi Widjaja (Founder and President Commissioner of Prodia) and Dewi Muliaty (President Director of Prodia) by Osmar Semesta Susilo, the Vice Director of MURI. The awards ceremony was held on Sunday, 7 May 2023, as part of Prodia’s 50th Anniversary Night Gala titled Golden Steps for the Future at the Ritz-Carlton Hotel, Mega Kuningan, Jakarta.

“This MURI award shows our commitment to raising the awareness of the likelihood of rare diseases. We would like to thank everyone and Prodia personnel for participating in this CSR program. Detection and definitive diagnosis of rare diseases align with the values of Prodia as the trusted personal and precise partner for health, providing precise and personalized diagnostic services. These values are integrated into this CSR program to showcase the company’s social contributions as it seeks to foster the wellness paradigm in relation to rare diseases in Indonesia. We believe that the program inspires and reminds customers, the public, the government, and every healthcare provider across Indonesia that we are all in this together when it comes to rare diseases,” said Dewi Muliaty, the Prodia President Director, in her speech during the ceremony.

Titled Bangun Paradigma Sehat Bersama Penyakit Langka (Building the Wellness Paradigm in Rare Diseases), this collaboration between Prodia and Indonesia Rare Disorders (IRD) is one of the company’s CSR programs held in celebration of its 50th anniversary. Through the program, Prodia provides complimentary genetic tests based on the chromosomal microarray analysis (CMA) method for 250 odalangkas. Those eligible for the test include individuals with congenital disorders, mental retardation, intellectual disability, and/or developmental delays. So far, 233 persons with rare diseases have registered, with 150 having taken the genetic tests after being scientifically selected. The engagement of medical practitioners, laboratory experts, genetic counselors, Prodia employees, strategic partners, the support from the management and the community, and the recommendation from the Indonesian Society of Human Genetics (InaSHG) helped Prodia secure the award.

“On Prodia’s 50th anniversary, we would like to reflect on our name—pro, Latin for for, and dia, Indonesian for he/she, meaning, ‘everyone who wants to enjoy our services’—and mark this milestone as a reaffirmation of our commitment to meaningful contributions to the nation going forward. We envision this CSR program as an altruistic act in the hope that it can educate the public on rare diseases and ease the burden on odalangkas. We hope that with the help of these tests, people with rare diseases can receive the right medical treatment and have access to a safe and comfortable space,” explained Andi Widjaja, the President Commissioner and the Founder of Prodia.

On the same occasion, Marina Amalia, the Corporate Secretary of Prodia, added, “As the leading medical laboratory, Prodia realizes its capability to serve the community and contribute to a better wellness paradigm. This series of Ministry of Health-endorsed CSR programs are taking place until September 2023.” They comprise educational webinars, genetic tests, and several stages of post-test counseling. Moving forward, the programs will take place regularly to advance the progress in the wellness paradigm with regard to rare diseases and odalangkas.

******